Veru Inc (VERU) - News Archive

Veru Inc. Unveils Promising Insights on Enobosarm and Broader Market Dynamics at ObesityWeek MIAMI, FL, Nov. 05, 2024 Veru Inc. (NASDAQ: VERU), a forward-thinking biopharmaceutical firm renowned for developing cutting-e...

Veru Inc. Engages Investors at BTIG Virtual Biotechnology Conference and Makes Progress with Enobosarm Clinical Trials for High-Quality Weight Loss Veru Inc. (NASDAQ: VERU), a late clinical-stage biopharmaceutical compa...

MIAMI, FL - Veru Inc. (NASDAQ: VERU), a leading biopharmaceutical company focused on developing groundbreaking medicines for muscle preservation, weight loss, oncology, and viral-induced acute respiratory distress syndr...

Combining the articles, we get the following sophisticated article:Veru to Present at the American Diabetes Association s 84th Scientific SessionsMIAMI, FL, June 10, 2024 - Veru Inc. (NASDAQ: VERU), a leading biopharmac...

Veru Inc. Announces Steven B. Heymsfield as Principal Investigator for Enobosarm Phase 2b Clinical Trial for High-Quality Weight LossMIAMI, FL, May 15, 2024 - Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceu...

Veru Inc. has recently commenced a Phase 2b clinical trial investigating the potential of enobosarm combined with semaglutide for high quality weight loss. This study is being conducted across 15 clinical sites in the U...

Veru Faces Delinquency Notice from Nasdaq, Highlighting Compliance IssuesMIAMI, FL, Feb. 27, 2024 - Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company, recently received a delinquency notification...

In a significant breakthrough for Veru, the pharmaceutical company recently announced the clearance of its Investigational New Drug (IND) application by the FDA. This crucial milestone paves the way for the initiation o...

Veru Inc., a leading biopharmaceutical company dedicated to addressing obesity and other critical medical conditions, recently submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administra...

Veru Inc., a leading late-stage biopharmaceutical company specializing in the development of innovative treatments for metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome, has announced t...